T cell surface antigens via polyclonal depletion

The entry "T cell surface antigens via polyclonal depletion" does not refer to a single molecular target or receptor. Instead, it describes a therapeutic strategy that uses antibodies—often polyclonal—to deplete multiple types of T cells by targeting various surface antigens. This approach is primarily used in transplantation medicine to reduce the risk of graft-versus-host disease by broadly suppressing the recipient's immune system. Methods include both physical and immunological techniques; the latter often employ anti-T cell antibodies such as alemtuzumab or anti-thymocyte globulin. While effective at reducing immune-mediated complications like GvHD, this strategy also increases susceptibility to infections and viral reactivations due to profound immunosuppression. This entry is not a canonical molecular target but rather an umbrella term for several molecules on the surface of T cells that are collectively targeted during therapeutic depletion protocols.

Other names

T cell depletionT-cell surface antigens (general)Polyclonal T cell depletion

Antibody-mediated lysis of multiple T cell surface antigens via polyclonal or monoclonal antibodies, leading to broad reduction in circulating and tissue-resident T cells